Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:gene_editing_therapy
|
| gptkbp:clinicalTrialPhase |
gptkb:New_Zealand
gptkb:United_Kingdom gptkb:United_States Phase 1 |
| gptkbp:companyStockSymbol |
gptkb:NTLA
|
| gptkbp:deliveredBy |
lipid nanoparticle
|
| gptkbp:developedBy |
gptkb:Intellia_Therapeutics
|
| gptkbp:firstInHuman |
2021
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_USA
|
| gptkbp:mechanismOfAction |
CRISPR-Cas9 gene editing
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:transthyretin_amyloidosis
|
| gptkbp:targetGene |
gptkb:TTR_gene
|
| gptkbp:therapeuticArea |
rare diseases
|
| gptkbp:bfsParent |
gptkb:Intellia_Therapeutics
|
| gptkbp:bfsLayer |
5
|
| https://www.w3.org/2000/01/rdf-schema#label |
NTLA-5001
|